Our Heritage is In Hematology

European Hematology Association Annual Congress 2020

Welcome Video from Chris Bowden, Agios Chief Medical Officer

Visit Our Booth

For 10 years, we have pioneered the science behind IDH mutations in hematologic malignancies and PKR activation in rare hemolytic anemias.

Unlocking the
Promise of IDH
in Hematologic


Explore IDH

Find out more about IDH mutations in hematologic malignancies and solid tumors.

is at our Core

Activating PKR
in Rare Hemolytic


Know PK Deficiency

Learn more about pyruvate kinase deficiency, a rare hemolytic anemia.

EHA 2020 Data Room

View our latest news and presentations from the EHA Annual Congress

Follow along with Agios at #EHA25Virtual

Follow @agiospharma

Contact Us

Medical Information Inquiries
  • Agios Medical Information Call Center
  • Monday – Friday 7:00am – 6:00pm CT
  • with Urgent After Hours

Driven by the desire to push boundaries, we combined our knowledge of the metabolome and the genome to develop precision medicines for patients with cancers that harbor IDH mutations starting with acute myeloid leukemia.

X Close

Our research platform was built around our deep understanding of metabolic pathways and precision medicine with the vision to develop transformational medicines for patients who need them.

X Close

Leveraging our prolific scientific platform, we are building a pipeline of disease-modifying medicines designed to significantly slow, halt or reverse rare genetic metabolic diseases.

X Close